key: cord-0717707-d2elhhsq
authors: Poor, Hooman D.
title: Pulmonary Thrombosis and Thromboembolism in COVID-19
date: 2021-06-19
journal: Chest
DOI: 10.1016/j.chest.2021.06.016
sha: b9a3652e90f31960401568d7c20b729088346467
doc_id: 717707
cord_uid: d2elhhsq

Coronavirus disease 2019 (COVID-19), the disease responsible for the devastating pandemic that began at the end of 2019, has been associated with a significantly increased risk of pulmonary thrombosis, even in patients receiving prophylactic anticoagulation. The predilection for thrombosis in COVID-19 may be driven by at least two distinct, but interrelated, processes: a hypercoagulable state responsible for large vessel thrombosis and thromboembolism, and direct vascular and endothelial injury responsible for in situ microvascular thrombosis. The presence of pulmonary thrombosis may explain why hypoxemia is out of proportion to impairment in lung compliance in some patients with COVID-19 pneumonia. Because pulmonary embolism and COVID-19 pneumonia share many signs and symptoms, diagnosing pulmonary embolism in patients with COVID-19 can be challenging. Given the high mortality and morbidity associated with severe COVID-19, and the concern that aspects of the disease may be driven by thrombosis, many hospital systems have instituted aggressive anticoagulation protocols above standard venous thromboembolism prophylaxis. In this review, the epidemiology, pathophysiology, diagnosis, and treatment of COVID-19 pulmonary thrombosis and thromboembolism are discussed.

In late December 2019, a cluster of patients with pneumonia of unknown etiology was linked to a seafood and wet animal wholesale market in Wuhan, China. 1 By early January 2020, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was isolated from these patients with virus-infected pneumonia, and soon after, the clinical syndrome caused by SARS-CoV-2 was labeled as coronavirus disease 2019 (COVID-19) by the WHO. 2 Since then, this highly transmissible and virulent disease has devastated the world, overwhelming hospitals with critically ill patients. A few notable observations about were made early in the course of the pandemic: 1) Many COVID-19 patients presented with markedly abnormal coagulation parameters, particularly D-dimer elevation, which correlated with mortality. 3 2) COVID-19 patients, particularly those in the intensive care unit (ICU), had a noticeably high incidence of thrombotic complications. 4 

patients demonstrated a high incidence of both pulmonary macro-and microthrombi despite the use of prophylactic anticoagulation. 5, 6 4) Many COVID-19 patients with respiratory failure appeared to have hypoxemia that was out of proportion to their impairment in lung compliance, a disconnect that could perhaps be explained by pulmonary thrombosis. 7 Given the high mortality and morbidity associated with severe COVID-19, 8, 9 and the concern that aspects of the disease may be driven by thrombosis, many hospital systems instituted aggressive anticoagulation protocols above standard venous thromboembolism (VTE) prophylaxis, despite the absence of randomized clinical trials supporting such practices. 10, 11 In this review, the epidemiology, pathophysiology, diagnosis, and treatment of COVID-19 pulmonary thrombosis and thromboembolism are discussed. Accurate assessments of the true incidence of VTE in hospitalized patients with COVID-19 remain elusive, with estimates ranging from 4.8% to 85%. 12 The significant variability in the reported incidence is likely a consequence of multiple factors, including assessment setting (e.g.

ICU vs non-ICU), type of events counted (e.g. symptomatic vs asymptomatic), testing strategies (e.g. clinical suspicion vs systematic screening), and degree of thromboprophylaxis. Given infection control concerns and strained resources during peak surge times early in the pandemic, the threshold for diagnostic testing with computed tomography pulmonary angiography (CTPA) and/or compression ultrasonography (CUS) was high, leading to a low frequency of testing. 13 In a meta-analysis by Jimenez consecutive COVID-19 patients admitted to the ICU during a one-month period in 2020, which was significantly higher than the 6.1% PE incidence for the 196 patients admitted to the ICU during the same time interval in 2019, despite similar severity of illness scores. 15 Helms et al. reported an 11.7% PE incidence in COVID-19 acute respiratory distress syndrome (ARDS) compared to a 2.1% PE incidence in a historical prospective cohort of non-COVID ARDS. 16 Critically ill patients in the ICU with COVID-19 have significantly higher rates of VTE and thrombosis than COVID-19 patients on the wards. Klok 13 For patients hospitalized with COVID-19, rates of developing PE after hospital discharge are low, reported to be 2% within the first six weeks post-discharge. 21 COVID-19 hospitalization does not appear to increase the risk of post-discharge VTE compared with hospitalization from other acute medical illnesses. 22 Systematic screening for VTE has been known to increase detection rates in non-COVID-19 patients. 23 Voicu et al. reported that 36% of mechanically ventilated COVID-19 patients were J o u r n a l P r e -p r o o f diagnosed with DVT within three days post-intubation when screened with CUS. 24 In COVID-19 patients on the wards, Santoliquido et al. demonstrated a DVT incidence of 12% with systematic screening, though the rate was 2.4% when counting only proximal DVT. 25 Mirsadraee et al. performed systematic whole-body CT scanning on 72 COVID-19 patients upon admission to the ICU, noting that 34 (47%) patients had PE, of which only 7% had been suspected clinically. 26 The presence of VTE in hospitalized COVID-19 patients is associated with greater disease severity and increased mortality. Patients with PE more frequently require mechanical ventilation and ICU admission, and have increased overall hospital length of stay. 27 In over 3000 consecutive hospitalized COVID-19 patients in a New York City hospital, after multivariable adjustment, both venous and arterial thrombosis were associated with increased mortality (adjusted hazard ratio 1.82). 28 It is unclear whether thrombosis is a direct cause of these worse outcomes or merely a marker of more severe disease.

Considering that VTE rates in patients hospitalized with COVID-19 are significantly higher than historical controls, there are likely other thrombotic mechanisms beyond the classic VTE risk factors of immobility and severe illness. 29 The predilection for thrombosis in COVID-19 is driven by at least two distinct, but interrelated, processes: a hypercoagulable state responsible for large vessel thrombosis and thromboembolism, and direct vascular and endothelial injury responsible for in situ microvascular thrombosis ( Figure 1 ). 30 J o u r n a l P r e -p r o o f

It was evident early in the pandemic that COVID-19 patients presented with abnormal hemostasis profiles, elevated D-dimer being the most frequent abnormality. 3 In a study of 2377 hospitalized COVID-19 patients in a New York hospital, 76% had elevated D-dimer at presentation. 31 D-dimer is a degradation product of fibrinolysis, and while a multitude of inflammatory processes can influence D-dimer levels, to some extent its elevation likely reflects intravascular thrombosis in COVID-19 patients. 32, 33 Elevated D-dimer has been shown to correlate with rates of thrombosis in COVID-19. 20, 27, 28 Mouhat et al. reported that a D-dimer greater than 2590 ng/mL was associated with a 17-fold increase in adjusted risk of PE in patients hospitalized with COVID-19. Li et al. noted that a greater than 50% increase in D-dimer level during hospitalization was the strongest independent predictor of symptomatic VTE in COVID-19 patients. 34 Elevated D-dimer levels are also independently associated with more severe disease and increased mortality in COVID-19. 9, 35 The biochemical coagulation phenotype in COVID-19 likely differs from disseminated intravascular coagulopathy (DIC) and sepsis-induced coagulopathy (SIC). DIC and SIC are consumptive coagulopathies, characterized by low platelet counts, decreased plasma levels of clotting factors, and prolongation of prothrombin time. 36 In contrast, neither platelet nor clotting factor consumption are common features in COVID-19, suggesting a different mechanism of coagulopathy in COVID-19. 37 For example, Huan et al. reported that in hospitalized COVID-19 patients, only 8% of ICU patients and 4% of non-ICU patients had platelet J o u r n a l P r e -p r o o f counts less than 100 x 10 9 /L on admission. 38 Helms et al. reported that while greater than 95% of COVID-19 patients in the ICU had elevated D-dimer and fibrinogen levels, none had a positive International Society of Thrombosis and Haemostasis DIC score. 16 Table 1 summarizes and compares the main coagulation parameters of DIC and COVID-19 coagulopathy.

Other commonly noted coagulation abnormalities in COVID-19 include dramatically increased thrombin production 39 and elevated concentrations of both von Willebrand factor (vWF) and factor V. 16, 40 Factor VIII, one of the more potent triggers of hypercoagulability, has been shown to be significantly increased in COVID-19. 41 Thromboelastography studies in severe COVID-19 demonstrate rapid clot formation with impaired fibrinolysis. 41 Additionally, platelets from patients with COVID-19 are activated more efficiently than are platelets from both healthy controls and patients with non-COVID-19 ARDS. 42 Immunothrombosis Elevated markers of systemic inflammation, particularly C-reactive protein and interleukin-6, are commonly observed in patients with COVID-19. 43 Extensive crosstalk occurs between the immune and coagulation systems to provide effective host defense. 44 Immune cells and inflammatory cytokines incite the development of immunothrombi, which consist of fibrin, monocytes, neutrophils, and platelets. By creating a sterile barrier against further pathogen invasion, these physiologic thrombi initially serve a protective purpose. 45, 46 However, dysregulation of thrombosis and inflammation can devolve into an injurious vicious cycle, leading to exuberant thrombosis with consequent organ dysfunction. 33, 47 The immune and coagulation systems are also linked via neutrophil extracellular traps (NETs), weblike structures J o u r n a l P r e -p r o o f of deoxyribonucleic acid decorated with antimicrobial proteins. NETs are expelled from neutrophils to physically capture and immobilize pathogens, and can also activate immunothrombosis. 48 NET levels have been shown to be elevated in COVID-19 patients when compared to controls, and also to correlate with disease severity. 49 

Autopsy studies early during the pandemic revealed diffuse endothelial inflammation in many organs, including the lung, heart, liver, and kidney, with evidence of direct viral infection of endothelial cells by the SARS-CoV-2 virus. 50 Because in-vivo biosynthesis of vWF is restricted to endothelial cells and megakaryocytes, high plasma vWF concentrations in patients with COVID-19 suggest significant endothelial cell derangement. 40, 41 Immune cell arteritis was found in the lungs of nearly half of cases in one COVID-19 autopsy series. 51 Endothelial injury, particularly in the context of a hypercoagulable milieu, is likely responsible for the high rates of microthrombosis noted in the pulmonary vasculature. While pulmonary microthrombosis has been noted previously in classical ARDS, 52 the extent evident in COVID-19 is significantly greater. Ackerman et al. noted that autopsies from patients with COVID-19 had nine times more alveolar capillary microthrombi compared to autopsies from patients with ARDS secondary to H1N1 influenza. 6 The high rates of microthrombosis are not limited to the lungs; they have also been reported in the heart 53 and skin. 54 Imaging studies demonstrate that thrombotic lesions in COVID-19 are smaller and more peripherally located compared to those in non-COVID acute PE, suggesting that some filling defects on CTPA, particularly isolated subsegmental PE, may reflect in situ pulmonary thrombosis instead of the typical embolization compliance. 56 Additionally, many non-intubated patients with COVID-19 demonstrate dramatic hypoxemia yet lack proportional signs of respiratory distress, a condition coined "happy hypoxemia." 57 Some have hypothesized that the presence of pulmonary thrombi, both micro and macro, may help explain the disconnect between gas exchange and lung compliance in severe COVID-19. 58

Pulmonary emboli increase pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP), with higher thrombotic burden correlating with higher PVR and PAP. 59 With sufficiently elevated RV afterload, pulmonary emboli can induce right ventricular (RV) dilation and dysfunction. 60 Somewhat strikingly, patients with COVID-19 requiring mechanical J o u r n a l P r e -p r o o f ventilation have invasive hemodynamic profiles that are characterized by low, not high, PVR. 61 This finding is surprising given the high prevalence of PE in COVID-19 patients in the ICU, as well as the high prevalence of elevated PVR in non-COVID ARDS. 62 It is possible that the hemodynamic effect of pulmonary thrombosis is mitigated by a primary pulmonary vasodilatory process in some patients with COVID-19. Dual-energy computed tomographic imaging has demonstrated pulmonary vessel dilation in COVID-19 pneumonia. 63 Ackerman et al., in addition to demonstrating high rates of pulmonary microthrombosis in COVID-19, also noted high rates of intussusceptive and sprouting angiogenesis. 6 Reynolds et al. reported that 83% of mechanically ventilated patients with COVID-19 had a positive bubble study as assessed by contrast-enhanced transcranial Doppler, likely indicative of abnormal pulmonary capillary dilation and/or pulmonary arteriovenous malformations. Additionally, the degree of transpulmonary bubble transit correlated with PaO 2 /FiO 2 ratio, suggesting that these pulmonary vascular dilations may be a significant cause of hypoxemia in COVID-19 ARDS. 64 While pulmonary macro-and microthrombi increase PVR, pulmonary vasodilation decreases PVR; when both processes occur simultaneously, each can "cancel out" the hemodynamic effect of the other (Figure 2 ). 65 The coexistence of both obliterative and vasodilatory processes in the pulmonary vasculature is reminiscent of what can occur in chronic liver disease, specifically portopulmonary hypertension (obliterative) and hepatopulmonary syndrome (vasodilatory). 66 Ultimately, in COVID-19 ARDS, the obliterative processes may dominate, leading to severe RV failure and cardiogenic shock. 67 While the vasodilatory and obliterative processes may offset each other hemodynamically, their coexistence may amplify hypoxemia in COVID-19. Vasodilated regions J o u r n a l P r e -p r o o f experience increased blood flow, creating low ventilation-perfusion ratios. Microthrombi and vasoconstriction in other areas of the lung reroute additional blood flow to the vasodilated regions and further drive down the ventilation-perfusion ratio. 65 Mathematical modeling demonstrates that the large amount of pulmonary venous admixture in the setting of relatively minor parenchymal involvement observed in early COVID-19 can be reasonably explained by a combination of pulmonary thrombosis and vasodilation. 68

In the absence of systematic screening, the diagnosis of PE begins with clinical suspicion.

Unexplained dyspnea and hypoxemia, particularly in the setting of a normal chest radiograph, raises the clinical suspicion for PE. 69 dimer levels did not discriminate between patients with and without PE. 26 Li et al. developed a "3-factor score" consisting of admission fibrinogen, admission D-dimer, and D-dimer increment greater than 1.5 fold, the score performing with a sensitivity of 0.93 and specificity of 0.71 for symptomatic VTE. 34 CTPA is the first-choice modality for the diagnosis of PE due to its high accuracy, wide availability, and ability to assess for other pulmonary pathologies. Its use may be limited in critically ill patients with COVID-19 who are not stable enough for transfer, and for patients with renal failure, a common complication in severe COVID-19. 73 Ventilation-perfusion scanning can be used for patients in whom CTPA is contraindicated or inconclusive. Scans performed on patients with abnormal chest radiographs, as is often the case in patients with COVID-19 pneumonia, are more likely to result in false positives because the images rarely appear as normal or low probability of PE in such patients. CUS can be performed to assess for DVT when chest imaging is contraindicated or indeterminate; however, the absence of DVT does not imply the absence of pulmonary thrombosis, especially since in situ pulmonary thrombosis is a potential mechanism in COVID-19. A diagnosis of DVT may eliminate the need to evaluate for PE as the indication for therapeutic anticoagulation will have been established.

Echocardiography can raise suspicion for the diagnosis of PE with the presence of clot in the right side of the heart or new right heart strain. While it has limited diagnostic value, echocardiography is most useful for risk stratification of confirmed PE. 74 J o u r n a l P r e -p r o o f

Considering that PE is one of the most common preventable causes of hospital death, 19 discontinued enrollment as statistical criteria for futility was met. Importantly, despite therapeutic anticoagulation decreasing major thrombotic events, there was an 89% probability that therapeutic anticoagulation was inferior to standard dose prophylactic anticoagulation in achieving the primary outcome of survival or days free of organ support. 80 The mechanism for this likely harm is unclear, given that major bleeding was only mildly increased with therapeutic anticoagulation (3.1% vs 2.4%). These findings suggest that initiating therapeutic anticoagulation after patients have developed severe COVID-19 disease may be too late to beneficially alter the clinical course. In contrast, for moderately ill hospitalized COVID-19 patients, the NIH recently announced via press release that therapeutic dose anticoagulation was superior to standard dose prophylactic anticoagulation in reducing the need for organ support and mortality. 81 The full results and official publication of these studies are anxiously J o u r n a l P r e -p r o o f awaited, as they will undoubtedly help establish the optimal anticoagulation dosing strategies for patients with COVID-19.

Anticoagulation is the mainstay of the treatment for acute PE, both for patients with and without COVID-19, in order to prevent further thrombosis and thromboembolism. 74 Initial treatment options for anticoagulation include unfractionated heparin, low molecular weight heparin, fondaparinux, and, in low-risk patients, direct oral anticoagulants. As is the case with non-COVID PE, risk stratification is the central tool used to identify patients at increased risk for early death who may benefit from reperfusion therapy (i.e. thrombolysis, embolectomy) and/or mechanical circulatory support. Per the European Society of Cardiology (ESC) guidelines, 74 "high-risk PE" is characterized by cardiac arrest, systolic blood pressure less than 90 mmHg, or requiring vasopressors and/or inotropes. "Intermediate-risk PE" is characterized by normotension with signs of RV dysfunction on echocardiography or CTPA, elevated troponin levels, or an elevated PE severity index (PESI) score. Of note, the role of troponin levels as a prognostic biomarker for PE in COVID-19 is confounded by the fact that troponin is frequently elevated in COVID-19 patients; 82 in that context it likely reflects myocardial inflammation and/or cardiac microthrombosis, rather than RV pressure overload. Low-risk PE is characterized by normotension, lack of RV dysfunction, and a low PESI score. Figure 3 summarizes the ESC risk stratification algorithm and treatment strategy. Given the risk of viral transmission from transporting COVID-19 patients to operating rooms and invasive laboratories, the use of procedural based therapies (e.g. surgical embolectomy, catheter-based therapies) may be limited in patients with PE and COVID-19. Ultimately, the use of PE Response Teams (PERT) can aid in providing multidisciplinary recommendations and rapid mobilization of resources. 83 Given the potential pathophysiologic role of pulmonary microthrombosis, thrombolysis has been used in small case series of COVID-19 ARDS. While these reports note improvement in hypoxemia, dead-space ventilation, and hemodynamics in patients with COVID-19 ARDS, the therapeutic responses appear to be short-lived. 58, 84 It is possible that concomitant anticoagulation during the administration of a thrombolytic is necessary to prevent immediate rethrombosis. 58 Currently, randomized trials evaluating the use of tissue plasminogen activator (NCT04357730) and tenecteplase (NCT045055920) in patients with COVID-19 ARDS are under way.

The author would like to acknowledge Jill Gregory from the Icahn School of Medicine at Mount Sinai for creating the illustrations in this manuscript.

J o u r n a l P r e -p r o o f Illustration showing how concomitant vasodilation can mitigate the hemodynamic effects of pulmonary thrombosis. Figure A portrays the normal pulmonary vasculature. Figure B demonstrates pulmonary thrombosis, which increases pulmonary vascular resistance and leads to increased pulmonary arterial pressure. Figure C shows how concomitant pulmonary vasodilation can potentially "cancel out" the increases in pulmonary vascular resistance and pulmonary arterial pressure caused by pulmonary thrombosis. 

A Novel Coronavirus from Patients with Pneumonia in China

The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome : Results From a Prospective

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19

Impact of high dose prophylactic anticoagulation in critically ill patients with COVID-19 pneumonia

Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study

Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19

The importance of a centralized line service during the COVID-19 pandemic

Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients

Identifying patients at risk of post-discharge complications related to COVID-19 infection

Postdischarge venous thromboembolism following hospital admission with COVID-19

Surveillance bias and deep vein thrombosis in the national trauma data bank: the more we look, the more we find

High Prevalence of Deep Vein Thrombosis in Mechanically Ventilated COVID-19 Patients

Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis

Prevalence of Thrombotic Complications in ICU-Treated Patients With Coronavirus Disease 2019 Detected With Systematic CT Scanning

Pulmonary embolism in patients with COVID-19 pneumonia

Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System

Risk factors for venous thromboembolism

Coagulopathy of Coronavirus Disease

Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients With COVID-19

Review of D-dimer testing: Good, Bad, and Ugly

Thrombosis and COVID-19 pneumonia: the clot thickens!

Clinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID-19 patients: A multicenter retrospective study

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation

Hematological Phenotype of COVID-19-Induced Coagulopathy: Far from Typical Sepsis-Induced Coagulopathy

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Covid-19-Associated Coagulopathy: Biomarkers of Thrombin Generation and Fibrinolysis Leading the Outcome

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study

Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis

Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19

Clinical and immunological features of severe and moderate coronavirus disease 2019

Hypercoagulopathy in Severe COVID-19: Implications for Acute Care

Multiple roles of the coagulation protease cascade during virus infection

SARS-2 Coronavirus-Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Thrombosis or Pulmonary Embolism?

COVID-19-associated coagulopathy: An exploration of mechanisms

Targeting potential drivers of COVID-19: Neutrophil extracellular traps

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Endothelial cell infection and endotheliitis in COVID-19

Tissue-specific Immunopathology in Fatal COVID-19

Pulmonary microthrombosis in severe adult respiratory distress syndrome

COVID-19-Associated Nonocclusive Fibrin Microthrombi in the Heart

Microthrombi in skin biopsy of a patient with COVID-19. JAAD Case Rep

Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: A different phenotype of thrombotic disease?

Physiological and quantitative CT-scan characterization of COVID-19 and typical ARDS: a matched cohort study

Why COVID-19 Silent Hypoxemia Is Baffling to Physicians

COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis

Lung perfusion scans and hemodynamics in acute and chronic pulmonary embolism

Acute right ventricular failure in the setting of acute pulmonary embolism or chronic pulmonary hypertension: a detailed review of the pathophysiology, diagnosis, and management

Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization

Pulmonary vascular dysfunction is associated with poor outcomes in patients with acute lung injury

Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT

Pulmonary Vascular Dilatation Detected by Automated Transcranial Doppler in COVID-19 Pneumonia

Positive Bubble Study in Severe COVID-19 Indicates the Development of Anatomical Intrapulmonary Shunts in Response to Microvascular Occlusion

Hepatopulmonary Syndrome and Portopulmonary Hypertension: The Pulmonary Vascular Enigmas of Liver Disease

Acute Cor Pulmonale in Critically Ill Patients with Covid-19

Modeling lung perfusion abnormalities to explain early COVID-19 hypoxemia

Clinical, laboratory, roentgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease

Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer

Wells Score to Predict Pulmonary Embolism in Patients with Coronavirus Disease

Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study

Acute kidney injury in patients hospitalized with COVID-19

ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis

Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study

Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial

Therapeutic Anticoagulation in Critically Ill Patients with Covid-19 -Preliminary Report. medRxiv

Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients

Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection

A Multidisciplinary Pulmonary Embolism Response Team: Initial 30-Month Experience With a Novel Approach to Delivery of Care to Patients With Submassive and Massive Pulmonary Embolism

Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series